IPM Take
This is not just a list of EU projects. It shows a shift from research activity toward implementation infrastructure. CAN.HEAL, PCM4EU, JA PCM, SPARC and related initiatives are starting to cover the real delivery chain: genomic data, molecular diagnostics, trial access, AI-supported decisions, training, patient engagement and policy recommendations. The next test is whether national systems adopt these outputs, instead of leaving them as successful EU project deliverables.
Executive Summary
On 4 February 2026, HaDEA published a World Cancer Day overview of EU-funded projects advancing personalised cancer medicine. The article highlights CAN.HEAL, PCM4EU, the Joint Action on Personalised Cancer Medicine, SPARC, CHIP-AML22, CGI-Clinics and Tumor-LN-oC. It states that CAN.HEAL and PCM4EU helped drive the launch of JA PCM, which started in November 2025 and brings together more than 140 organisations from 29 countries. The projects cover genomic data use, molecular diagnostics, clinical decision support, cross-border trial access, AI-supported tools, professional training, paediatric AML diagnostics, patient engagement and sustainable implementation.
Why it matters
- Public authorities: Need to turn EU-funded project outputs into national cancer pathways, procurement choices, reimbursement rules and implementation plans.
- Hospitals / providers: Should watch which tools become usable in routine care, especially molecular diagnostics, decision support, training and trial-access models.
- Patients / advocates: Should push for project results to reduce access gaps, not only demonstrate excellence in selected centres or consortia.
Before this kind of coordinated portfolio, personalised cancer medicine in Europe often developed through separate research initiatives, national centres and disease-specific pilots. That created innovation, but not always equal access.
HaDEA’s overview shows a more connected model emerging. CAN.HEAL contributed to genomics and public health integration. PCM4EU worked on molecular diagnostics, clinical decision support and trial access. JA PCM now brings more than 140 organisations from 29 countries around personalised prevention, personalised medicine, follow-up and tertiary prevention. SPARC is positioned to support a more unified European approach, including harmonisation, AI-driven decision support, training and patient engagement.
The eligibility logic is broad. This is not about one medicine or one cancer type. It concerns people at risk of cancer, diagnosed patients, survivors, children with rare blood cancers and patients who need molecular profiling or access to precision oncology trials.
The implementation test is whether these outputs become routine practice across Europe. For IPM, the signal is clear: Europe is building pieces of the personalised cancer medicine infrastructure. The next question is whether Member States can absorb them into funded, measurable and equitable delivery pathways.
